Abcam, ab264622, Rat Sclerostin ELISA Kit (SOST)

Size: 1 x 96Tests
Rat Sclerostin ELISA Kit (SOST) is a single-wash 90-min Simplestep used to quantify Rat Sclerostin (SOST) with a sensitivity of 13 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Heparin Plasma, Citrate plasma, Serum, EDTA Plasma,
Reacts with:Rat,
Assay type:Sandwich (quantitative),
Sensitivity:= 13 pg/mL,
Range:15.63 - 1000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Rat Sclerostin ELISA Kit (SOST) (ab264622) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Sclerostin (SOST) protein in cit plasma, edta plasma, hep plasma, and serum. It uses our proprietary SimpleStep ELISA® technology. Quantitate Rat Sclerostin (SOST) with 13 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (
ab203359
) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
Sclerostin (SOST) is a key player in bone formation. With its signaling partners, SOST inhibits Wnt signaling pathway and leads to a reduction in bone formation. Mutation of its controlling gene, SOST, can lead to a rare bone overgrowth disorder called Van Buchem disease. Anti-sclerostin antibodies are currently under investigation as a treatment for osteoporosis. The antibodies for this kit were raised against the full-length mature protein, which shares 95% and 89% identity with the mouse and human proteins, respectively.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Sclerostin also known as SOST is a glycoprotein weighing approximately 22 kDa. It is predominantly expressed in osteocytes the most abundant cells found in bone. Sclerostin is an extracellular molecule that plays a role in bone metabolism by inhibiting the Wnt signaling pathway which is important for bone formation. This protein acts as a negative regulator of bone growth by binding to the LRP5/6 receptors. Inhibitors such as 'anti-sclerostin' antibodies have been developed to block its function and promote bone formation.
Biological function summary
Sclerostin inhibits osteoblastic activity and formation by interfering with bone morphogenetic proteins. It doesn’t form part of a large protein complex but interacts directly with cell surface receptors. Its expression decreases in response to mechanical loading on bones which is an important part of regulating bone density and remodeling. By controlling osteoblast function sclerostin contributes to skeletal homeostasis an essential process for maintaining bone strength and integrity.
Pathways
Several mechanisms regulate sclerostin activity. In the canonical Wnt/β-catenin signaling pathway it serves as an important checkpoint that ensures controlled bone formation. Sclerostin acts by preventing the activation of LRP5/6 receptors pivotal components in this pathway. Additionally it shares a regulatory network with dickkopf-1 (DKK1) another Wnt inhibitor both of which have an influence on bone metabolism and development.
Two primary conditions associated with sclerostin are osteoporosis and sclerosteosis. Osteoporosis arises from excessive inhibition of bone formation and is characterized by fragile bones due to decreased bone mass. On the other hand sclerosteosis results from mutations in the SOST gene leading to excessive bone growth. Sclerostin's interaction with proteins like DKK1 clarifies its role in bone density management and highlights its relevance in therapeutic strategies targeting these conditions.